| Literature DB >> 31358025 |
Antonio Messina1, Antonio Dell'Anna2,3, Marta Baggiani4, Flavia Torrini2,3, Gian Marco Maresca2,3, Victoria Bennett5, Laura Saderi6, Giovanni Sotgiu6, Massimo Antonelli2,3, Maurizio Cecconi7,8.
Abstract
BACKGROUND: Bedside functional hemodynamic assessment has gained in popularity in the last years to overcome the limitations of static or dynamic indexes in predicting fluid responsiveness. The aim of this systematic review and metanalysis of studies is to investigate the reliability of the functional hemodynamic tests (FHTs) used to assess fluid responsiveness in adult patients in the intensive care unit (ICU) and operating room (OR).Entities:
Keywords: End-expiratory occlusion test; Fluid responsiveness; Functional hemodynamic test; Mini-fluid challenge
Mesh:
Year: 2019 PMID: 31358025 PMCID: PMC6664788 DOI: 10.1186/s13054-019-2545-z
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Flow of the studies. FC, fluid challenge; ICU, intensive care unit; FA, atrial fibrillation; OR, operating room; FHT functional hemodynamic test
Characteristics of the functional hemodynamic tests and of the fluid challenges
| Studies | General characteristics | FC characteristics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | FCs | Months | Ventilatory setting | FHT: description | Volume infused (ml) | Time (min) | Rate (ml/min) | Reference variable | Type of fluid | Hemodynamic monitoring | FR (%) | ||
| Operating room | Guinot et al. [ | 42 | 42 | NS | CMV | EEOT: ventilation interrupted for 15 s | 500 | 10 | 50 | SV > 15% | Ringer | CardioQ | 67 |
| Biais et al. [ | 41 | 41 | 6 | CMV | EEOT: ventilation interrupted for 30 s | 250 | 10 | 25 | SVI ≥ 10% | Saline | ProAQT | 51 | |
| Biais et al. [ | 44 | 88 | 12 | CMV | Mini-FC: 100 ml in 120 s | 250 | 10 | 25 | SVI ≥ 10% | Saline | ProAQT | 32 | |
| Guinot et al. [ | 73 | 73 | 6 | SB | Mini-FC: 100 ml in 60 s | 500 | 10 | 50 | SV > 15% | Ringer | NICCOMO | 37 | |
| Preisman et al. [ | 18 | 70 | NS | CMV | RSVT: decrease in SAP after successive incremental pressure-controlled breaths (10, 20, and 30 cmH2O) | 250 | 5 | 50 | SVI ≥ 15% | Poligeline 3.5% | PiCCO | 46 | |
| Biais et al. [ | 28 | 28 | 12 | CMV | LRM: 30 cmH20/30 s | 250 | 10 | 25 | SVI ≥ 10% | Saline | ProAQT | 57 | |
| De Broca et al. [ | 60 | 60 | 9 | CMV | LRM: 25 cmH20/25 s | 500 | 10 | 50 | SV ≥ 15% | Ringer | CardioQ | 62 | |
| Intensive care unit | Wu et al. [ | 50 | 50 | 8 | CMV | Mini-FC: 50 ml in 10 s | 500 | 15 | 33 | CO ≥ 15% | Crystalloids (undefined) | TTE | 54 |
| Smorenberg et al. [ | 21 | 21 | NS | CMV | Mini-FC: 100 ml in 120 s | 500 | 20 | 25 | CO > 10% | Hydroxyethyl starch 6% | Modelflow/PulseCO | 62 | |
| Muller et al. [ | 39 | 39 | 10 | CMV | Mini-FC: 100 ml in 60 s | 500 | 15 | 33.3 | VTI ≥ 15% | 6% HES | TTE | 54 | |
| Monge Garcia et al. [ | 30 | 30 | 6 | SB | Airway pressure elevated up to 30 cmH20 for 10 s | 500 | 30 | 16.6 | SVI ≥ 15% | 6% HES | Flow-Trac | 37 | |
| Perel et al. [ | 14 | 14 | NS | CMV | RSVT: decrease in SAP after successive incremental pressure-controlled breaths (5,10, 15, and 20 cmH2O) | 7/kg | 30 | NA | CI ≥ 15% | Plasma expander (undefined) | PAC | 57 | |
| Yonis et al. [ | 33 | 33 | 40 | CMV | EEOT: ventilation interrupted for 15 s | 500 | 15 | 33.3 | CI ≥ 15% | Crystalloids (undefined) | PiCCO | 45 | |
| Xiao-ting et al. [ | 48 | 48 | 8 | CMV | Mini-FC: 100 ml in 60 s | 500 | 15 | 33.3 | CI ≥ 10% | Saline | PiCCO | 71 | |
| Mallat et al. [ | 49 | 49 | NS | CMV | Mini-FC: 100 ml in 60 s | 500 | 15 | 33.3 | CI ≥ 15% | 4% albumin | PiCCO | 45 | |
| Georges et al. [ | 50 | 50 | NS | ACV(V); no SE | EEOT: ventilation interrupted for 12 s | 500 | 15 | 33.3 | CO ≥ 15% | Saline | TTE | 56 | |
| Wilkman et al. [ | 20 | 20 | NS | CMV | PEEP elevated from 10 to 20 cmH2O for 60–120 s | 6/kg | 30 | NA | CO ≥ 15% | Succinilgelatine 4% | TEE | 30 | |
| Jozwiak et al. [ | 30 | 30 | 14 | ACV(V); no SE | EEOT: ventilation interrupted for 15 s | 500 | 10 | 50 | CI > 15% | Saline | PiCCO | 50 | |
| Monnet et al. [ | 34 | 34 | NS | ACV(V); SE | EEOT: ventilation interrupted for 15 s | 500 | 10 | 50 | CI > 15% | Saline | PiCCO | 68 | |
| Myatra et al. [ | 20 | 30 | NS | ACV(V); no SE | 7/kg | 10 | NA | CI > 15% | Saline | PiCCO | 53 | ||
| Monnet et al. [ | 54 | 54 | NS | ACV(V); no SE | EEOT: ventilation interrupted for 15 s | 500 | 20 | 25 | CI ≥ 15% | Saline | PiCCO | 55 | |
FC fluid challenge, CMV controlled mechanical ventilation, ACV(V) volume-assist controlled mechanical ventilation, SB spontaneously breathing patients, SE spontaneous efforts, EEOT end-expiratory occlusion test, V tidal volume, MV mechanical ventilation, LRM lung recruitment maneuver, RSVT respiratory systolic variation test, SAP systolic arterial pressure, PEEP positive end-expiratory pressure, CO cardiac output, CI cardiac index, SV stroke volume, SVI stroke volume index, FR fluid responsiveness, HES 6% hydroxyethyl starch 6%, TEE trans-esophageal echocardiography, TEE transthoracic echocardiography, PAC pulmonary artery catheter; NA not applicable; CardioQ, Deltex Medical Ltd., Chichester, UK; PiCCO/ProAQT, PULSION Medical Systems; FloTrac, Edwards Lifesciences, Irvine, CA, USA; NICCOMO, non-invasive continuous cardiac output, Imedex, France; PulseCO, LiDCOltg, Cambridge, UK; Modelflow, FMS, Amsterdam, the Netherlands
QUADAS-2 score assessment of the included studies
| Studies | Patient selection | Index test | Reference standard | Flow and timing | Final score | Final risk | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk of bias | Applicability judgments | TOT | Risk of bias | Applicability judgments | TOT | Risk of bias | Applicability judgments | TOT | ||||||||||||
| Operating room | Guinot et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 9 | L |
| Biais et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 3 | Low | 1 | 10 | M | |
| Biais et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
| Guinot et al. [ | Unclear | 2 | High | 3 | 5 | Low | 1 | Low | 1 | 2 | High | 3 | Low | 1 | 4 | Low | 1 | 12 | H | |
| Preisman et al. [ | High | 3 | High | 3 | 6 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 11 | H | |
| Biais et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | High | 3 | 11 | H | |
| De Broca et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
| Intensive care unit | Wu et al. [ Smorenberg et al. [ | UncleaR | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L |
| Low | 1 | High | 3 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | High | 3 | 11 | H | ||
| Muller et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
| Monge Garcia et al. [ | Low | 1 | Unclear | 2 | 3 | Low | 1 | Unclear | 2 | 3 | High | 3 | Low | 1 | 4 | High | 3 | 13 | H | |
| Perel et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | High | 3 | 11 | H | |
| Yonis et al. [ | Unclear | 2 | High | 3 | 5 | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | 11 | H | |
| Xiao-ting et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | High | 3 | 10 | H | |
| Mallat et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 9 | M | |
| Georges et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 9 | M | |
| Wilkman et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | High | 3 | 11 | H | |
| Jozwiak et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
| Monnet et al. [ | High | 3 | Low | 1 | 4 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 9 | M | |
| Myatra et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
| Monnet et al. [ | Unclear | 2 | Low | 1 | 3 | Low | 1 | Low | 1 | 2 | Low | 1 | Low | 1 | 2 | Low | 1 | 8 | L | |
For each study, the risk of bias is calculated as the sum of the four categories; we calculated the sum of these points. L = studies showing a score below the median of the sums of all studies. H = studies showing a score above the median of the sums of all studies. M = studies showing a score equal to the median of the sums of all studies
Reported ROC values of the included studies
| Studies | Functional hemodynamic test | Parameter | AUC (95%CI) | Sensitivity (%) | Specificity (%) | Y | +PV | −PV | +LR | −LR | Threshold | GZ high | GZ low | Pt in GZ (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating room | Guinot et al. [ | EEOT: ventilation interrupted for 15 s | DELTA SV (%) | 0.78 (0.63–0.89) | 82 | 71 | NA | 85 | 67 | 2.87 | 0.25 | 2.3 | NA | NA | NA |
| Biais et al. [ | EEOT: ventilation interrupted for 30 s | DELTA SV (%) | 0.91 (0.81–1.0) | 100 | 81 | 0.81 | 84 | 100 | NA | NA | 5 | 8 | 4 | 17 | |
| Biais et al. [ | Mini-FC: 100 ml in 120 s | DELTA SV (%) | 0.95 (0.90–0.99) | 93 | 85 | 0.78 | NA | NA | NA | NA | 6 | 7 | 4 | 19 | |
| Guinot et al. [ | Mini-FC: 100 ml in 60 s | DELTA SV (%) | 0.93 (0.84–0.97) | 89 | 89 | NA | 83 | 93 | 8.18 | 0.12 | 7 | 8 | 3 | 14 | |
| Preisman et al. [ | RSVT: decrease in SAP after successive incremental pressure-controlled breaths (10, 20, and 30 cmH2O) | RSVT (slope, mmHg/cmH2O) | 0.96 (0.92–1.0) | 93 | 89 | NA | NA | NA | NA | NA | 0.51 | NA | NA | NA | |
| Biais et al. [ | LRM: 30 cmH20/30 s | DELTA SV (%) | 0.96 (0.81–0.99) | 88 | 92 | NA | NA | NA | NA | NA | 30 | − 22 | − 37 | 36 | |
| De Broca et al. [ | LRM: 25 cmH20/25 s | DELTA SV (%) | 0.95 (0.91–0.99) | 92 | 96 | 0.92 | 100 | 89 | NA | NA | 16 | − 15 | − 17 | 8 | |
| Intensive care unit | Wu et al. [ | Mini-FC: 50 ml in 10 s | DELTA VTI (%) | 0.83 (0.69–0.96) | 74 | 95 | NA | 94 | 79 | NA | NA | 9 | NA | NA | NA |
| Smorenberg et al. [ | Mini-FC: 100 ml in 120 s | DELTA CO (%) | 0.85 (0.63–0.97) | NA | NA | NA | 92 | 88 | NA | NA | 2.3 | NA | NA | NA | |
| Muller et al. [ | Mini-FC: 100 ml in 60 s | DELTA VTI (%) | 0.92 (0.78–0.98) | 95 | 78 | NA | NA | NA | NA | NA | 3 | NA | NA | NA | |
| Monge Garcia et al. [ | Airway pressure elevated up to 30 cmH20 for 10 s | DELTA PP (%) | 0.98 (0.84–0.99) | 91 | 95 | NA | 91 | 95 | NA | NA | 52 | NA | NA | NA | |
| Perel et al. [ | RSVT: decrease in SAP after successive incremental pressure-controlled breaths (5,10, 15, and 20 cmH2O) | RSVT (slope, mmHg/cmH2O) | 0.89 (0.72–1.0) | 87.5 | 83 | NA | NA | NA | NA | NA | 0.24 | NA | NA | NA | |
| Yonis et al. [ | EEOT: ventilation interrupted for 15 s | DELTA CI (%) | 0.65 (0.46–0.84) | 33 | 100 | NA | NA | NA | INF | 0.67 | 10 | 11 | − 4 | 79 | |
| Yonis et al. [ | Trendelemburg maneuver | DELTA CI (%) | 0.9 (0.8–1.0) | 87 | 89 | NA | NA | NA | 7.9 | 0.15 | 8 | 12 | 5 | 30 | |
| Xiao-ting et al. [ | Mini-FC: 100 ml in 60 s | DELTA CI (%) | 0.83 (0.69–0.96) | 73.2 | 60.6 | NA | NA | NA | NA | NA | 5.4 | NA | NA | NA | |
| Mallat et al. [ | Mini-FC: 100 ml in 60 s | DELTA CI (%) | 0.78 (0.64–0.88) | 77 | 74 | NA | NA | NA | NA | NA | 5.2 | 12.6 | − 1.5 | 67 | |
| Georges et al. [ | EEOT: ventilation interrupted for 12 s | DELTA VTI (%) | 0.96 ± 0.03 | 89 | 95 | 0.85 | NA | NA | NA | NA | 9 | 10 | 6 | 20 | |
| Wilkman et al. [ | PEEP elevated from 10 to 20 cmH2O for 60–120 s | DELTA MAP (%) | 0.91 (0.77–1.0) | 83 | 86 | NA | 71 | 92 | NA | NA | − 10.2 | NA | NA | NA | |
| Jozwiak et al. [ | EEOT: ventilation interrupted for 15 s | DELTA CI (%) | 0.98 (0.85–1.0) | 93 | 100 | 0.93 | NA | NA | NA | NA | 4 | NA | NA | NA | |
| Monnet et al. [ | EEOT: ventilation interrupted for 15 s | DELTA CI (%) | 0.97 (0.85–0.99) | 91 | 100 | NA | NA | NA | NA | NA | 5 | NA | NA | NA | |
| Myatra et al. [ | DELTA PPV (%) | 0.99 (0.98–1.0) | 94 | 100 | NA | 100 | 93 | NA | NA | 3.5 | NA | NA | NA | ||
| Myatra et al. [ | DELTA SVV (%) | 0.97 (0.92–1.0) | 88 | 100 | NA | 100 | 88 | NA | NA | 2.5 | NA | NA | NA | ||
| Myatra et al. [ | EEOT: ventilation interrupted for 15 s (6 ml/kg ventilation) | DELTA CI (%) | 0.44 (0.23–0.66) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Myatra et al. [ | EEOT: ventilation interrupted for 15 s (8 ml/kg ventilation) | DELTA CI (%) | 0.95 (0.88–1.0) | 88 | 93 | NA | 93 | 78 | NA | NA | 4.1 | NA | NA | NA | |
| Monnet et al. [ | EEOT: ventilation interrupted for 15 s (Crs < 30 cmH2O/ml) | DELTA CI (%) | 0.97 ± 0.03 | 93 | 91 | 0.85 | 93 | 91 | NA | NA | 5 | NA | NA | NA | |
| Monnet et al. [ | EEOT: ventilation interrupted for 15 s (Crs > 30 cmH2O/ml) | DELTA CI (%) | 0.93 ± 0.05 | 93 | 92 | 0.84 | 93 | 92 | NA | NA | 5 | NA | NA | NA |
The area under the receiving operating characteristic (ROC) curve (AUC) of each study is reported as median (25th–75th interquartile) or mean (± standard deviation), as stated in the original article
NA data not available, CI cardiac index, CO cardiac output, SV stroke volume, SVI stroke volume index, SVV stroke volume variation, PPV pulse pressure variation, VTI velocity time integral, RSVT respiratory systolic variation test, PP pulse pressure, MAP mean arterial pressure, SAP systolic arterial pressure, ND not defined, Vt tidal volume, Crs respiratory compliance, EEOT end-expiratory occlusion test, LRM lung recruitment maneuver, RSVT respiratory systolic variation test, PEEP positive end-expiratory pressure, FC fluid challenge, Y Youden index, +PV positive predictive value, −PV negative predictive value, +LR positive likelihood ration, −LR negative likelihood ratio, GZ gray zone, Pt patients, INF infinite
Fig. 3EEOT forest plot of included studies. Forest plot reporting the pooled sensitivity and specificity (green diamonds) of the end-expiratory occlusion test (EEOT) in predicting of fluid responsiveness by considering the changes in stroke volume or its surrogates after the test and those induced by fluid challenge administration. Black squares represent the values of sensitivity and specificity (with 95% confidence intervals; black lines) of each study included in the metanalysis, and the size of each square indicates the size of each study. The definitions Monnet et al. “a” and “b” refer to the two populations investigated in the study [50] (see also Table 3 and see text for details). 95%CI, 95% confidence intervals
Fig. 4Mini-FC forest plot of included studies. Forest plot reporting the pooled sensitivity and specificity (green diamonds) of the mini-fluid challenge (mini-FC) in predicting fluid responsiveness by considering the changes in stroke volume or its surrogates after the test and those induced by fluid challenge administration. Black squares represent the values of sensitivity and specificity (with 95% confidence intervals; black lines) of each study included in the metanalysis, and the size of each square indicates the size of each study. 95%CI, 95% confidence intervals
Fig. 5Clinical algorithm for EEOT and mini-FC application in the ICU and the OR. In the OR, FHTs can be added to the dynamic indexes evaluation, considering the gray zone reported in the literature [21]. When PPV or SVV values range within the gray zone, we suggest the use of the EEOT, as the first step. A clear positive response (SV increase > 5%) suggests fluid responsiveness, whereas a negative/uncertain response could be further investigated by the consequent use of the mini-FC, as indicated. In critically ill patients, the need of FC administration is often evaluated combining different signs and measurements [58]. In this context, the EEOT (in patient undergoing controlled mechanical ventilation) and the mini-FC (in patients retaining to some extent a spontaneous breathing effort) can be useful when the PLR is unsuitable.*We suggest a FC of 4 ml/kg [55] over 10 min. **Intra-abdominal hypertension; uncontrolled pain, cough, discomfort, and awakening; hip/leg fractures; uncontrolled intracranial hypertension. ICU, intensive care unit; OR, operating room; FC, fluid challenge; PLR, passive leg raising; CMV, controlled mechanical ventilation; SB, spontaneously breathing patients; AMV, assisted mechanical ventilation; PPV, pulse pressure variation; SVV, stroke volume variation; EEOT, end-expiratory occlusion test; SV, stroke volume